LBM declined. Further investigation should be done to determine whether this increase in grip strength is associated with improvements in morbidity or quality of life. Curiously, an increase in grip strength was not seen in the delayed supplementation group although weight and LBM improved at a faster rate than in the early supplementation group.
Ultimately, the investigators saw no effect of supplementation on viral load at any of the time points in their study and similar to the other studies in our systematic review, all groups showed significant declines in viral load 3 months after ART initiation, as would be expected. Although there was some suggestion of an improvement in CD4 + cell counts with whey protein, this effect diminished 3 months after supplementation ended.
Finally, as Olsen et al observe in their article, the scale-up of nutritional supplementation that Ethiopia undertook for all patients with HIV and BMI ,18.5 after the study ended did not seem to fare well, with more than 70% of patients defaulting from supplementation. Although the delayed intervention design is one that should be encouraged more widely in research studies of nutritional supplementation to answer some of the remaining scientific questions, it is clear that information from these types of efficacy trials is not enough to translate promising results into policy. A case study or an effectiveness trial of the program in Ethiopia could provide important information on how countries can successfully scale-up nutritional assessment, counseling, and support and avoid some of the challenges that Ethiopia has faced. To the Editors:
The article by Koller et al 1 is a welcome effort to document trends and determinants of immunodeficiency among children living with HIV starting combination antiretroviral therapy (cART) in low-, middle-, and highincome countries and highlights the very modest improvements in the stage at which children begin cART. The article raises several questions which would benefit from further consideration.
Interpreting the findings in this article would be enhanced if there was more information about the sites within each country that contributed data such as how many sites, what level of care were they (clinic or hospital), public or private, nongovernmental or research-based service settings, and rural or urban areas. Without this level of detail on the sites, it is difficult to determine whether these results represent "best case" scenarios, and consequently the situation in "non-international epidemiologic databases to evaluate AIDS (IeDEA)" sites is likely to be much worse. According to the IeDEA Web site (http://www.iedea-sa.org), the main criterion for clinics to participate in the IeDEA collaboration is that a clinic treats people with HIV and prospectively and electronically collects clinical data. In low-and middle-income country (LMIC) settings, this inclusion criterion would likely have limited the sample of facilities to those receiving some donor or research support. Routine health information systems in many LMIC countries have been characterized as weak, 2, 3 and it is unlikely that electronic data would be the norm for national health management information systems in these settings. 3, 4 Using the group of upper-middle income countries as an example, 83% of the sample comes from 1 country, South Africa, where all except 1 IeDEA site is situated in the metropolitan areas of Cape Town and Johannesburg, the exception being a clinic in Hlabisa, KwaZulu-Natal, which is a rural demographic surveillance site. The finding that around 63% of children in these research sites in South Africa started cART with severe immunodeficiency is concerning because the situation is likely to be considerably worse in general public health facilities without additional research support and without electronic prospective tracking systems. Similarly, 82% of the sample for the lower middle-income countries comes from Zambia, and within Zambia from 1 nongovernmental organization (Centre for Infectious Disease Research in Zambia), situated in Lusaka. Although the findings are important in improving our knowledge of the progress with access to pediatric cART, having clear information on the source of the data is also critical to improve the utility of the findings for national governments and health managers.
We agree with the conclusion of Koller et al 1 that early diagnosis of HIV in children must remain a global public health priority, and we have shown it is still a major missed opportunity in South Africa. 5 We highlight, though, an important issue affecting initiation of cART among children, which is not discussed in this article, the notion of pediatric HIV disease and treatment as a neglected disease. 6 Although there is evidence of a worldwide decline in vertical HIV transmission, a high number of children still become infected with HIV. 7 In a country such as South Africa where there have been significant declines in perinatal HIV transmission, 8 The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that 16,000 (95% confidence interval: 14,000 to 19,000) children 0-14 years were newly infected in 2013. 7 Given the complexity of pediatric HIV treatment, it is not surprising that there is late initiation of cART during the first years of life. Treatment options 9 Drugs produced by different companies vary in bottle size and special storage needs. Some carry unpleasant tastes and risks of toxicity.
10 Dosage adjustments depending on weight are needed up to 3 times in the first year of life alone. Procurement of pediatric drugs is complex and forecasting of demand is difficult with a market only a fraction of the size of the adult market. This also leads to prices twice as expensive as the adult equivalents. 11 We propose that unless more child-friendly formulations are developed, late cART initiation of children is likely to continue. It is also likely that the situation will be even worse in busy nonresearch health settings in LMICs.
